Tradestie Institutional Equity Comparison Engine

DMAC vs ARCT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ARCT counters with relative strength in Valuation. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ARCT at 2.5x Forward P/E and -311.2% operating margin (+6.7% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against ARCT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ARCT
DMAC N/M vs ARCT 2.5x Fwd P/E
Growth & Margin Winner DMAC
Op Margin 0.0% vs -311.2% ยท YoY +0.0% vs +6.7%
Momentum & Technical Winner DMAC
1Y +55.3% vs +10.8% ยท 52W Pos 55% vs 25%
Options & Structure Winner DMAC
SURGE (14th %ile IV) vs BREAKDOWN (7th %ile IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
ARCT NASDAQ
Arcturus Therapeutics Holdings Inc. Common Stock
Pharmaceutical Preparations
$8.61
+2.99% 1D
Market Cap $241.0M
1M Return -16.73%
1Y Return +10.81%
Forward P/E 2.5x
Unified AI Score
57.7 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 72.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% ARCT +10.81% Spread: +44.45 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DMAC Revenue ARCT Revenue DMAC Op. Margin ARCT Op. Margin Margin Edge
FY2018 $0M $20M -1352.2% -138.5% ARCT
FY2019 N/A $20M N/A -122.7% ARCT
FY2020 N/A $10M N/A -749.8% ARCT
FY2021 N/A $10M N/A -1641.3% ARCT
FY2022 N/A $210M N/A 5.9% ARCT
FY2023 N/A $170M N/A -46.9% ARCT
FY2024 N/A $150M N/A -62.8% ARCT
FY2025 N/A $80M N/A -93.0% ARCT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (5) vs ARCT (5)
Institutional Metric DMAC ARCT Criterion Row Winner
Market Capitalization Scale $503.1M $241.0M Larger Scale DMAC
Trailing P/E Ratio Valuation N/M 2.5x Lower Multiple ARCT
Forward P/E Ratio Valuation N/M 2.5x Lower Multiple ARCT
Revenue Growth (YoY) Growth +0.0% +6.7% Higher Growth ARCT
Operating Margin (TTM) Profitability 0.0% -311.2% Higher Margin DMAC
Net Profit Margin Profitability 0.0% -285.9% Higher Margin DMAC
Return on Equity (ROE) Capital Efficiency -114.6% -44.4% Higher ROE ARCT
52-Week Range Position Momentum 55% ($5โ€“$11) 25% ($6โ€“$18) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 2.03ฮฒ ยท 127% Vol Lower Realized Risk DMAC
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 57.7 / 100 (HOLD) Higher Composite ARCT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs ARCT Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARCT BREAKDOWN
42d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live ARCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor ARCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.